Seattle Genetics, Inc. (NASDAQ:SGEN)

CAPS Rating: 3 out of 5

A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.

Recs

0
Player Avatar MDmomma (< 20) Submitted: 2/8/2012 3:40:53 PM : Outperform Start Price: $18.97 SGEN Score: +10.61

proprietary methods for linking antibody to cytotoxic drugs has potential to revolutionize chemotherapy

Report this Post Reply

Featured Broker Partners


Advertisement